



PROGRAM

Tuesday, June 12, 2007

19:00 – 21:00 Welcome Dinner – Lighthouse Garden, Hilton

Wednesday, June 13, 2007

Morning Sessions

- 8:15 Opening Remarks and Introduction of Plenary
Charles Boucher; University Medical Center Utrecht, the Netherlands
- 8:30 Overcoming the challenges of the Caribbean HIV epidemics
Nick Adomakoh; The Ladymeade Reference Unit, Ladymeade Gardens, Barbados

RESISTANCE TO NEW ANTIRETROVIRAL AGENTS

Chairs: Raymond Schinazi, Emory University/VA Medical Center, USA
Charles Boucher; University Medical Center Utrecht, the Netherlands

- 9:00 R1206, a representative of a new class of potent diphenylether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species
Klaus Klumpp; Roche, USA
- 9:15 IMPACT OF BASELINE NNRTI MUTATIONS ON THE VIROLOGIC RESPONSE TO TMC125 IN THE PHASE III CLINICAL TRIALS DUET-1 AND DUET-2
Johan Vingerhoets; Tibotec, Belgium
- 9:30 Strategic Flexibility of the Nonnucleoside RT Inhibitor TMC278 Explains Its Potency Against Drug-Resistant Mutants
Kalyan Das; Rutgers University, USA
- 9:45 BREAK
- 10:15 ANTI-HCV ACTIVITY AND CELLULAR PHARMACOLOGY OF 2'- METHYLCYTIDINE ALONE AND IN COMBINATION WITH NON-TOXIC CONCENTRATIONS OF RIBAVIRIN IN THE HCV REPLICON SYSTEM
Brenda Hernandez-Santiago; Emory University/VA Medical Center, USA
- 10:30 Synergy of a Hepatitis C virus (HCV) NS4A antagonist, ACH-806, in combination with HCV protease or polymerase inhibitors
David Wyles; University of California, San Diego, USA

- 10:45 Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis of Protocol 005, a Phase 2 Study in Patients with Triple-Class Resistant HIV-1 Infection
Daria Hazuda; Merck Research Labs, USA
- 11:00 Resistance and Cross-Resistance to First Generation Integrase Inhibitors: Insights from a Phase 2 Study of Elvitegravir (GS-9137)
Damian McColl; Gilead Sciences, Inc, USA
- 11:15 Impact of Gag Cleavage Site Mutations on the Virologic Response to Darunavir/Ritonavir in Treatment-Experienced Patients in POWER 1, 2 and 3
Inge Dierynck; Tibotec, Belgium
- 11:30 Structural Basis for the Resistance Profile of the HIV-1 Protease Inhibitor PL-100
Joseph Vacca; Merck Research Laboratories, USA
- 11:45 In Vitro HIV-1 Resistance Selection to GS-8374, a Novel Phosphonate Protease Inhibitor: Comparison with Lopinavir, Atazanavir, and Darunavir.
Christian Callebaut; Gilead Sciences, Inc, USA
- 12:00 Lunch

Afternoon Sessions

- 13:30-15:30 Poster Viewing Session I
Resistance to New Antiretroviral Agents, Epidemiology, and HBV/HCV Posters
- 15:30-16:30 Themed Discussion: Epidemiology
Carlo-Federico Perno; Universita Di Tor Vergata, Italy
- 17:30-21:30 Harbour Master Dinner Cruise**

Thursday, June 14, 2007
Morning Session

ENTRY INHIBITION

Chairs: Douglas Richman, University of California/VA Medical Center, San Diego, USA
Michael Greenberg, Trimeris, Inc., USA

- 8:30 CCR5 Binding Properties of a CCR5 Small Molecule Inhibitor with High Antiviral Potency Against A Maraviroc-Resistant HIV-1 Strain
Gabrielle Heilek; Roche Palo Alto LLC, USA
- 8:45 In vivo Emergence of HIV-1 Resistance to the CCR5 Antagonist Vicriviroc: Findings from ACTG A5211
Athe Tsibris; Massachusetts General Hospital, USA
- 9:00 HIV-1 Isolates Resistant to CCR5 Antagonists Demonstrate Increased Affinity for the Drug-Bound Coreceptor
Peter Buontempo; Schering Plough Research Institute, USA
- 9:15 Mutations in the co-receptor binding region of the HIV-1 envelope confer resistance to the CCR5 inhibitor SCH-C (SCH 351125)
Wei Huang; Monogram Biosciences, USA
- 9:30 Current Implementations of HIV Genotyping Algorithms are Inadequate for the Prediction of X4 Co-Receptor Usage in Clinical Isolates from Population-Based V3 Sequences: Approaches to improvement.
Viviane Lima; BC Centre for Excellence in HIV/AIDS, Canada
- 9:45 Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays
Ina Vandenbroucke; Virco BVBA, Belgium
- 10:00 BREAK
- 10:30 CXCR4-using Virus Detected in Patients Receiving Maraviroc in the Phase 3 studies MOTIVATE 1 and 2 Originates from a Pre-existing Minority of CXCR4-using Virus
Marilyn Lewis; Pfizer Global Research and Development, UK
- 10:45 Differential co-receptor use by dual-tropic HIV-1 envelopes impacts co-receptor inhibitor susceptibility
Jonathan Toma; Monogram Biosciences, USA
- 11:00 Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and MOTIVATE 2
Julie Mori; Pfizer Global Research and Development, UK
- 11:15- 11:45 Themed Discussion: Entry Inhibition
Richard Harrigan; BC Centre for Excellence in HIV/AIDS, Canada
- 11:45-12:30 Panel Discussion
- 12:30 Lunch

Thursday, June 14, 2007

Afternoon Sessions

13:30 - 15:30 Poster Viewing Session II
Clinical Implications of Resistance and HIV Pathogenesis, Fitness and Resistance Posters

HIV PATHOGENESIS, FITNESS AND RESISTANCE

Chairs: Charles Boucher; University Medical Center Utrecht, the Netherlands
Daniel Kuritzkes, Brigham and Women's Hospital, USA

15:30 Sustained Restriction of Viral Diversity following Interruption of Antiretroviral Treatment
Günthard Huldrych; University Hospital Zurich, Switzerland

15:45 How HIV-1 Selects Copackaged RNAs: Implications for Antiviral Strategies Targeting RNA Dimerization Initiation Signal
Wei-Shau Hu; National Cancer Institute, USA

16:00 Intermittent Antiretroviral Prophylaxis with Tenofovir and Emtricitabine Protects Macaques Against Repeated Rectal SHIV Exposures
J. Gerardo Garcia-Lerma; Centers for Disease Control and Prevention, USA

16:15 Impact of HR1 Enfuvirtide Resistance Mutations on Sensitivity to HR2 Directed Neutralizing Antibodies
Ashley Barry; Trimeris, Inc., USA

Free Evening to enjoy Barbados

Friday, June 15, 2007

Morning Sessions

- 8:30 Introduction of Plenary
François Clavel, Inserm U552, France
- 8:35 Role of Gag polyproteins and proteolysis in HIV assembly and maturation
Hans-Georg Kraeusslich; University of Heidelberg, Germany

MECHANISMS OF HIV DRUG RESISTANCE

Chairs: Brendan Larder, RDI, UK
François Clavel, Inserm U552, France

- 9:15 Silent Mutations at RT codons 65 and 66 are Very Strongly Associated with Treatment and Drug Resistance and are Implicated in Reverse Transcription Efficiency.
Richard Harrigan; BC Centre for Excellence in HIV/AIDS, Canada
- 9:30 Competition with the Nucleic Acid Substrate Can Present an Obstacle in the Development of RNase H Active Site Inhibitors
Matthias Götte; McGill University, Canada
- 9:45 HIV-1 Reverse Transcriptase Mutations A371V and Q509L Decrease DNA-Dependent RNase H Cleavage and Increase the Rate of AZT-MP Excision
Jessica Brehm; University of Pittsburgh, USA
- 10:00 BREAK
- 10:30 Probing the Mechanism by Which Connection Domain Mutations Enhance AZT Resistance: Mutational Analysis of the RNase H Primer Grip
Krista Delviks-Frankenberry; National Cancer Institute, USA
- 10:45 In vitro Molecular Characterization of the development of the K65R and M184V mutations in Subtype C HIV-1
Dimitrios Coutsinos; McGill University AIDS Centre, Canada
- 11:00 Circumventing Drug Resistance: Using the Substrate Envelope Hypothesis to Develop Robust Novel HIV-1 Protease Inhibitors.
Celia Schiffer; University of Massachusetts Medical School, USA
- 11:15 A Novel Genetic Pathway Involving L76V & M46I Leading to Lopinavir/r Resistance
Annemarie Wensing; University Medical Center Utrecht, the Netherlands
- 11:30-12:15 Panel Discussion
- 12:15 Lunch

Friday, June 15, 2007

Afternoon Sessions

13:30-15:30 Poster Viewing Session III
Mechanisms of HIV Drug Resistance and New Resistance Technologies and Interpretations Posters

NEW RESISTANCE TECHNOLOGIES AND INTERPRETATIONS

Chairs: John Mellors, University of Pittsburgh, USA
Robert Grant, Gladstone/UCSF, USA

15:30 Novel Electrophoretic Tag-Based in vitro Assay to Quantify Dimerization of p66 and p51 Subunits of HIV-1 Reverse Transcriptase (RT)
Soumi Gupta; Monogram Biosciences, USA

15:45 Prevalence of Low Abundant Drug Resistant Variants by Ultra-deep Sequencing in Chronically HIV-infected Antiretroviral (ARV) Naïve Patients and the Impact on Virologic Outcomes
Michael Kozal; Yale University School of Medicine, USA

16:00 DNA Bar Coding and Pyrophosphate Sequencing Reveals Rare HIV Drug Resistance Mutations of Potential Clinical Significance
Gary Wang; University of Pennsylvania School of Medicine, USA

CLINICAL IMPLICATIONS OF RESISTANCE

16:15 Drug Resistance at Virologic Failure in a Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-Sparing Regimens for Initial Treatment of HIV-1 infection (ACTG 5142)
Richard Haubrich; University of California San Diego, USA

16:30 Protease Gene Mutations In a Trial Comparing First Line Lopinavir/ritonavir Monotherapy to Lopinavir/ritonavir + Zidovudine/Lamivudine (MONARK Trial)
Constance Delaugerre; Hopital Ambroise Pare, France

16:45 Closing Remarks

19:30 Awards' Dinner – Charles Fort, Hilton